## Un-diagnosing persistent adult asthma

<table>
<thead>
<tr>
<th>Journal:</th>
<th><em>European Respiratory Journal</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>ERJ-01433-2017.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Research Letter</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>01-Aug-2017</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Jabbal, Sunny; University of Dundee, Scottish Centre for Respiratory Research  
Lipworth, Brian; University of Dundee, Asthma & Allergy Research Group |
| Key Words: | exhaled nitric oxide, asthma, airway hyperresponsiveness |

This is the pre-peer reviewed version of the following article: Un-diagnosing persistent adult asthma, BJ Lipworth, S Jabbal, ERJ, 1 Nov 2017 which has been published in final form at DOI:10.1183/13993003.01433-2017. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Un-diagnosing persistent adult asthma

1Brian J Lipworth, 1Sunny Jabbal
1Scottish Centre for Respiratory Research, Ninewells Hospital & Medical School, Dundee, Scotland, DD1 9SY

Correspondence to: Dr BJ Lipworth, Scottish Centre for Respiratory Research, Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY.
Tel: +44 1382 383188 b.j.lipworth@dundee.ac.uk

The diagnosis of asthma is usually based on typical symptoms, family history, audible wheeze, peak flow, spirometry, possibly in conjunction with atopy and blood eosinophilia, as well as response to treatment. In cases where the diagnosis is less clear cut other tests may be required including impulse oscillometry (IOS), exhaled breath nitric oxide (FeNO) and bronchial challenge testing (Figure).

A commonly seen pattern in our asthma clinic would be a non-smoking patient presenting to primary care with an episode of viral associated persistent cough and wheeze, initially unresponsive to salbutamol and antibiotic, with a normal chest radiograph, negative sputum culture, normal peak flow, with or without normal spirometry. Such cases may then be given empirical treatment with inhaled corticosteroid (ICS) which may be continued in the longer term especially if symptoms take time to resolve. This also assumes that an alternative diagnosis has already been pursued in patients with persistent cough.

There is a psychological burden to an individual being diagnosed with asthma in addition to the on-going costs of treatment along with the potential for ICS related adverse effects. Once patients have been told they have asthma and on maintenance therapy it may be difficult to persuade them that either the initial diagnosis was incorrect or that they may have had an intermittent episode of asthma that subsequently resolved.

Diurnal variability on serial peak flow recordings may be a useful pointer to asthma but requires a motivated patient to properly perform and record accurate readings. Reversibility of spirometry to inhaled salbutamol (≥15% and ≥200ml increase in FEV1) is only useful for patients who have impaired FEV1 <80% predicted where there is potential room for bronchodilator response. For patients with a preserved FEV1 >80% predicted, or for patients who cannot perform adequate spirometry, it may be useful to consider using IOS which requires less cooperation being an effort independent test carried out during normal tidal breathing (1). A diagnosis of asthma may be supported by the
presence of heterogeneity of airway resistance as the difference between 5Hz and 20Hz (R5–R20>0.07 kPa/L.s) and salbutamol reversibility ≥ 40% (2, 3).

One of the hallmarks of asthmatic inflammation is the presence of underlying airway hyper-responsiveness (AHR), as measured by bronchial challenge testing using either direct (methacholine or histamine) or indirect (mannitol) acting stimuli (4). Ideally such a challenge test should be performed having first stopped ICS for at least two weeks in order to avoid the possibility of a false negative result. Our pragmatic regimen is to half the dose of ICS every week until a 200ug beclometasone equivalent dose is achieved, where upon it can be stopped, followed by repeat lung function and if required a challenge test two weeks later. The worsening of symptoms in association with obstructive lung function at this visit upon stopping ICS may be diagnostic in itself and obviate the need for performing challenge.

The dose related suppressive effects of ICS on AHR are more pronounced for indirect than direct acting challenges (5, 6). Hence if a challenge test is to be performed while still taking ICS, either methacholine or histamine should be used rather than mannitol. The American Thoracic Society advocate a cut off value for methacholine challenge as the provocative concentration to produce a 20% fall in FEV1 (PC20) of ≤4mg/ml being indicative of positive AHR, whereas a cut off >4≤8mg/ml is considered as being borderline (7). However, the guidelines do not stipulate whether these PC20 cut offs refer to patients on or off ICS. We and others recommend a pragmatic cut off value for PC20 ≤8mg/ml for direct challenge (8, 9). We also advocate measuring FeNO off ICS, the reason for stopping treatment is that FeNO is maximally suppressed by low dose ICS after 1-2 weeks, while values return back to baseline after 1 week of ICS washout (10). ICS naïve patients with positive AHR (PC20 ≤8mg/ml) also have higher FeNO levels than those who are AHR negative (11). In this regard an elevated FeNO ≥ 35 parts per billion (12) is highly predictive of persistent asthma for a patient not currently using ICS.

Prior to challenge for patients taking combination inhalers the long acting beta-agonist (LABA) moiety should be stopped for one week while converting to ICS alone followed by tapering. The additional effect of LABA and leukotriene receptor antagonist (LTRA) on AHR amounts to less than one doubling dilution (13, 14), so that one week off such therapy should be sufficient washout in most cases. There is uncertainty about the protective effects of anti-cholinergics on AHR(15-17). Long acting muscarinic antagonists should be the first drug withdrawn for one week (18), prior to stopping LABA as part of sequential step down therapy.

In a real life study of community diagnosed asthma patients, there were 30% who were non responsive to both methacholine and mannitol challenges, where the median beclometasone equivalent dose was 1000ug, 68% were taking LABA and 19% LTRA (9). In comparison to the 70% who were responders to challenge, there were significant differences in values for mean FEV1 (88 vs 100%), mean FeNO (26 vs 16 parts per billion), asthma control questionnaire score (1.07 vs 0.55) and skin prick positive response (79 vs 50%). A Canadian study found 28%
of patients with a physician based diagnosis who had no evidence of asthma when their treatment was tapered and evaluated using direct challenge testing, with an estimated cost saving £2100 for each undiagnosed patient (19). In a further multicentre study from Canada using a similar protocol current asthma was ruled out in 33% of cases, and after further 12 month follow up 29% continued to have no evidence of asthma (8).

Patients with a negative challenge test along with normal FeNO and IOS who have persistent symptoms having stopped ICS should then go on to have further tests perhaps including upper and lower airway endoscopy, high resolution CT thorax scan and gas diffusion in order to exclude possible alternative diagnoses such as chronic rhino-sinusitis, lung cancer, bronchiectasis and pulmonary embolism.

Word count = 1022

Figure Legend: Flow chart for decision making in difficult cases where there may be uncertainty about the diagnosis of persistent adult asthma.

References:


Figure Legend: Flow chart for decision making in difficult cases where there may be uncertainty about the diagnosis of persistent adult asthma.

445x623mm (96 x 96 DPI)